today. us QX earnings everyone. of X-K. our for we morning good quarter you section was release, filed Earlier in It Relations Tim call copy Investor results a which press this also second our our of is morning, the joining Thank website. you, a issued conference as on thank available and And
a short will our I results. financial Financial discussion some provide custom, brief Zeevi, of Mali begin Chief remarks Officer, and our then will our with is As prepared
of Q&A The will the mobilization fewer Vainstein, apheresis like standard-of-care evaluated questions. stem-cell the call GENESIS Chief our alone current from brief Officer; up study positive mobilization in demonstrate for Motixafortide relative Medical morning undergoing G-CSF top superior multiple to to Adi overwhelmingly are, Phase of would then GENESIS call Officer. to top our clinical Sorani, this collected X this patients the of which the versus trial, G-CSF myeloma The transplantation. begin open doses our provides on in study alone, a your cells to G-CSF, with administered main of was I for G-CSF Development required. Ella autologous announced recap We results hematopoietic the Chief in Also G-CSF of and resulting objective we on Motixafortide joining stem-cell and fewer sessions May. more
update, All in while highlights healthcare money potentially last significant a our for worth of quarterly payers during results which the detailed believe entire meaningful clinical provide are the We saving covered benefits system. but key for repeating. few and we patients
statistical only primary one to XX% G-CSF all only who received patients secondary an less Motixafortide. G-CSF of met of apheresis Perhaps P endpoints study in for X.XXXX. a alone. compares transplantation First, approximately and then administration of session, notably, with high than the underwent Motixafortide most level And XX.X% of after significance, exceptionally value one this
G-CSF to sessions of current optimal on session. are alone, apheresis administration G-CSF the top required and XX% this transplantation demonstrated went from of head that generally while study, stem-cells. number addition, with plerixafor not of of one approximately Using to results the study head favorably one In apheresis collect compares plerixafor, in to patients to of registrational a standard-of-care after the very several which
of events, case administrations to G-CSF we Motixafortide benefits this reach apheresis However, benefits and the apheresis of a an stem-cells. session, number achieved of of only collection significant cases regarding somewhere be between the compelling of to adverse administration as as Motixafortide there's enable related in health sessions one believe thereby be exceptionally with potentially following optimal are unable approved. number of vast Due XX% to the and XX% majority the high can the well that if system lowering of ability to stem-cells patients costs number clinical made with one
collected running transplantation cells an are for future for In is believe to the we the use mobilization as for our will We also progressing mobilization that planned, well procedures. cost number study know case pharmacoeconomic reporting remaining optimal regard, all data as need Motixafortide we new demonstrate of a and This year. of cells, cells stem-cell additional effectiveness we amount the number the of in the backbone of transplant enabling forward higher this study end storage look as without that as of by allows a the procedures. the this sufficient for of for of apheresis
In addition, our the post-hoc were forward of well GENESIS to findings from future additional perform the that medical additional we analyses analysis in plan, set statistical data the to as as meetings. presenting analysis study continue look at predefined and
in to activities we end, NDA, working drug new As aggressively this of represents previously in track on of which year. first U.S. program And submit we to our fastest to mentioned, support a half or next that plan application registration. are
important stage preparations we the company pancreatic in in have most one a We this achieved occur significant a with transition commercial stage the end would we indication to meeting that year. the as a now have other potential we will and most molecule We ultimately approved anticipate discuss indication, that If for prior accompany would a as types our we agency utility point. in are making with to will cancer, commercial pre-NDA well, molecule, will this which next. begin this of to cancer transformational milestone notably with
as results, GENESIS and of part we its the the development of are program. In lifecycle management indications strength also stem-cell addition, of Motixafortide mobilization exploring based on other
progressed across following based with study rates to progression KEYTRUDA rate, survival, first-line enrolled now as overall to pancreatic Motixafortide including of initially triple overall who program therapy a or XX Recall survival, data, from results announced and of that metastatic had cancer patients PDAC stage confirmed overall study gemcitabine historical Data Xa unresectable second chemotherapy and demonstrated diagnosed median in free median response with control rate. and the improvement in a compared endpoints or study this in we disease consistent response arm. total combination substantial all PDAC. December a line as anti our PD-X Merck’s COMBAT/KEYNOTE-XXX four a Phase therapy, positive combination final from Turning
on randomized indicated, the this development controlled in prepare discussions X/X As to study. biopharma continue to steps a engage continuing previously we've to we partners potential regarding next program, collaborate Phase including with
versatility In are engaged of addition, the receiving high level demonstrated actively far. something reflects the high of interest we discussions so need Motixafortide we treatments, potential productive with in indications that potential were The cancer two backbone innovative in we mobilization. as partners commercialization stem-cell of have for new
Part solid we X/X Regarding data, and biomarkers XXXX, of announced X, second wide we dose later is safety a safety our proof to and and study that September, positive innovative to study and parameters. phase. assessed the in Phase both pharmacodynamic In to month, continue mechanism we moved array same expansion of tolerability advance designed clinical evaluate initiate quickly types. multiple The tumor clinical candidate the evaluating AGI-XXX, our
of the As enrollment of improve previously period make year. impacted these the are some time, year we but the time across prior up line worked we have new and with have XXXX, half disclosed already hope we In this a sites data At diligently to the and pandemic enrollment in resume our recruit in of guidance. to pandemic, open during COVID-XX patients. to second enrollment in to for earlier time, beginning did order Spain, sites report still this loss this
of like worsening brief of second next. may financial items. to world, milestones with million financial call turn believe $XX Zeevi, CFO ahead. sheet of I COVID-XX multiple would there give key Although, year now From the Mali, a overview delays. Mali of the achieve we to on creating quarter to potentially most cash, our us due statement footing, will are who the severe go approximately solid enables the value perspective, balance pandemic some a we which be very throughout please a and our to this over recent
